Clinical trials
Follow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
Yiqi Jiedu Tongluo
- Development stage
- Phase 2
- Lead developer
- Shanghai Pulmonary Hospital, Tongji University
- Administration
- Oral
01
Overview
Yiqi Jiedu Tongluo is a Traditional Chinese Medicine (TCM) formula, often prepared as a decoction. It is investigated as an adjunctive therapy in oncology, particularly for advanced non-small cell lung cancer where it aims to delay targeted drug resistance when combined with EGFR-TKIs. Additionally, it has been studied in advanced esophageal squamous cell carcinoma in combination with Western chemotherapy regimens (camrelizumab, apatinib, and S-1), demonstrating potential to improve Traditional Chinese Medicine syndromes, enhance patient quality of life, prolong survival, and mitigate adverse effects such as nausea, vomiting, diarrhea, and fatigue associated with the conventional treatments. While its precise molecular mechanism of action is not fully elucidated in the provided context, its therapeutic role appears to involve modulating the body's response to cancer and conventional therapies.
- Other names
- Yiqi Jiedu Tongluo DecoctionYiqi Jiedu Tongluo Prescription益气解毒通络方
02
Targets
AKT1 (Proto-oncogene serine/threonine-protein kinase Akt1)CASP3 (Caspase-3)ESR1 (ERα)ICAM1 (Intercellular Adhesion Molecule 1)IL1B (Interleukin-1 beta)MMP2 (Matrix metalloproteinase-2)TGFB1 (Transforming growth factor Beta-1 proprotein)TP53 (Cellular Tumor Antigen p53 R175H)
Beyond the preview
Go deeper on Yiqi Jiedu Tongluo.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Explore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Trace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Explore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Compare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Connect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on Yiqi Jiedu Tongluo.